Glycyx

Glycyx is a biotechnology firm founded in 2020 with a mission to address a critical issue in oncology. The company's groundbreaking approach focuses on preventing the negative impact of opioids on the efficacy of immunotherapy. Glycyx aims to significantly improve the survival rates and the quality of life for cancer patients worldwide. The recent Series A investment in the company, received on 01 July 2023, marks an important milestone in the evolution of this transformative startup. The investment comes at a time when Glycyx is Phase 2 ready and has completed CMC, with clinical supply built through Phase 3. Glycyx's novel therapeutic solution aims to counteract the negative effects of opioids on immune checkpoint inhibitor therapies without compromising pain relief. The company's small molecule peripherally restricted opioid antagonist, axelopran, has demonstrated robust safety credentials and efficacy in preclinical studies. It possesses the potential to reverse Opioid-Induced Immunosuppression and enable re-challenge in treatment-resistant cancers. By addressing the challenge of Opioid-Induced Immunotherapy Failure (OIIF), Glycyx stands at the forefront of innovation in cancer treatment. The company's pioneering efforts have the potential to bring about a paradigm shift in the way cancer care is approached, offering new hope to patients and healthcare professionals.